Combination molecular therapies for spinal muscular atrophy: How much is enough?
- PMID: 33118639
- DOI: 10.1002/mus.27109
Combination molecular therapies for spinal muscular atrophy: How much is enough?
Comment on
-
Combination molecular therapies for type 1 spinal muscular atrophy.Muscle Nerve. 2020 Oct;62(4):550-554. doi: 10.1002/mus.27034. Epub 2020 Aug 10. Muscle Nerve. 2020. PMID: 32710634
References
REFERENCES
-
- Harada Y, Rao VK, Arya K, et al. Combination molecular therapies for type 1 spinal muscular atrophy. Muscle Nerve. 2020;62(4):550-554. https://doi.org/10.1002/mus.27034. Epub 2020 Aug 10. PMID: 32710634.
-
- Lee BH, Collins E, Lewis L, et al. Combination therapy with nusinersen and AVXS-101 in SMA type 1. Neurology. 2019;93(14):640-641. https://doi.org/10.1212/WNL.0000000000008207. Epub 2019 Sep 5. PMID: 31488615.
-
- Mercuri E, Lucibello S, Perulli M, et al. Longitudinal natural history of type I spinal muscular atrophy: a critical review. Orphanet J Rare Dis. 2020;15(1):84. https://doi.org/10.1186/s13023-020-01356-1. PMID: 32248834; PMCID: PMC7132885.
-
- Finkel RS, Mercuri E, Darras BT, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377(18):1723-1732. https://doi.org/10.1056/NEJMoa1702752. PMID: 29091570.
-
- Waldrop MA, Karingada C, Storey MA, et al. Gene therapy for spinal muscular atrophy: safety and early outcomes. Pediatrics. 2020;146(3):e20200729. https://doi.org/10.1542/peds.2020-0729. PMID: 32843442.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
